Selective effect of imatinib on serum IgM in a patient with CML [1]

International Journal of Hematology

Volumn 80, Issue 4, 2004, Pages 381-382

  Nagasawa, Masayuki ^a   Mizutani, Shuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; HYDROXYUREA; IMATINIB; IMMUNOGLOBULIN M;

ADOLESCENT; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SELECTIVITY; FEVER; HEADACHE; HEPATOSPLENOMEGALY; HUMAN; LETTER; MALE; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOGLOBULIN M; LEUKEMIA, MYELOID, CHRONIC; MALE; PIPERAZINES; PYRIMIDINES;

EID: 9444288216     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04105     Document Type: Letter

References (7)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
2. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer. 2002;38:S28-36.
3. Raanai P, Goldman JM, Ben-Bassat I. Challenges in oncology, case 3: depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol 2002;20:869-870.
4. Hrose J, Kouro T, Yokota T, et al. A developing picture of lymphopoiesis in bone marrow. Immunol Rev. 2002;189:28-40.
5. Waskow C, Paul S, Haller C, et al. Viable c-kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. Immunity. 2002;17:277-288.
6. Waskow C, Rodewald HR. Lymphocyte development in neonatal and adult c-kit-deficient (c-kitW/W) mice. Adv Exp Med Biol. 2002;512:1-10.
7. Steegmann JL, Moreno G, Alaez C, et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon α and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica. 2003;88:762-768.